BPG is committed to discovery and dissemination of knowledge
Articles in Press
9/17/2026 9:29:20 AM | Browse: 12 | Download: 0
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Prognostic value of triglyceride-glucose index in advanced esophageal squamous cell carcinoma treated with camrelizumab plus nab-paclitaxel and/or cisplatin
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zi-Xuan Wei, Yan Wang, Jia-Yao Xu, Jie Yan and Yan-Ru Qin |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82273381 |
|
| Corresponding Author |
Yan-Ru Qin, MD, Department of Oncology, Zhengzhou University First Affiliated Hospital, No. 1 Longhu Zhonghuan Road, Jinshui District, Zhengzhou 450000, Henan Province, China. yanruqin@163.com |
| Key Words |
Triglyceride-glucose index; Esophageal squamous cell carcinoma; Immunotherapy; Chemotherapy; Insulin resistance; Objective response rate; Survival |
| Core Tip |
The triglyceride glucose (TyG) index is an emerging, easily accessible marker of insulin resistance that independently predicts poorer treatment response and survival in patients with advanced or metastatic esophageal squamous cell carcinoma undergoing immunotherapy with camrelizumab and chemotherapy (nab-paclitaxel/cisplatin). A high TyG index is significantly associated with a lower objective response rate (23.7% vs 55.6%) and worse progression-free survival and overall survival. The TyG index may aid in patient stratification and inform treatment decisions for advanced esophageal squamous cell carcinoma, potentially improving clinical outcomes. |
| Citation |
Wei ZX, Wang Y, Xu JY, Yan J, Qin YR. Prognostic value of triglyceride-glucose index in advanced esophageal squamous cell carcinoma treated with camrelizumab plus nab-paclitaxel and/or cisplatin. World J Gastroenterol 2026; In press
|
 |
Received |
|
2026-06-12 07:35 |
 |
Peer-Review Started |
|
2026-06-12 07:35 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2026-07-15 06:06 |
 |
Revised |
|
2026-07-31 13:41 |
 |
Publication Fee Transferred |
|
2026-08-26 03:44 |
 |
Second Decision by Editor |
|
2026-09-17 02:42 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2026-09-17 09:29 |
 |
Articles in Press |
|
2026-09-17 09:29 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.